Jeena Sikho Lifecare Limited has announced the publication of three academic papers in the International Journal of Advanced Research (IJAR), showcasing the company's commitment to evidence-based Ayurvedic research and clinical practice. The company informed stock exchanges about these publications under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Published Research Papers

The three publications authored by medical professionals associated with Jeena Sikho Lifecare Limited include the Managing Director, senior consultants, and Ayurvedic experts. These research papers demonstrate the company's ongoing dedication to advancing Ayurvedic medicine through documented clinical evidence.

Research Significance

These publications in the International Journal of Advanced Research highlight the company's approach to integrating traditional Ayurvedic principles with modern clinical documentation. The case studies and reports cover critical health conditions including chronic liver disease, chronic kidney disease, and prostatomegaly, demonstrating the therapeutic effectiveness of Ayurvedic treatments.

The research papers showcase various Ayurvedic treatment methodologies including Nidan Parivarjan (cause avoidance), Ahar (dietary modifications), Vihar (lifestyle changes), and Shaman Chikitsa (therapeutic treatments). This comprehensive approach reflects the company's holistic treatment philosophy.

Company Profile

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, focusing on providing freedom from diseases and drugs through traditional Ayurvedic medicine. The company maintains its registered office in Zirakpur, Punjab, and corporate office in New Delhi, with a mission centered on "Health | Wealth | Happiness."

The publication of these research papers reinforces the company's position in evidence-based Ayurvedic healthcare and its commitment to advancing traditional medicine through scientific documentation and peer-reviewed research.

Jeena Sikho Lifecare Limited has formally notified stock exchanges about an upcoming investor and analyst meeting scheduled for March 23, 2026. The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details and Participants

The investor meeting will feature key company representatives including Mr. Manish Grover, Managing Director of the company, and Dr. Ish Sharma. They will engage with various categories of institutional investors during this interaction session.

Institutional Investor Categories

The meeting will include participation from multiple types of institutional investors:

• Mutual Fund representatives
• Insurance Fund managers
• AIF/PMS participants
• Alternative Investment professionals
• Private Equity Fund representatives

Regulatory Compliance and Information Sharing

The company has emphasized its commitment to regulatory compliance by ensuring that no unpublished price sensitive information will be shared during the meeting. This adherence to disclosure norms reflects the company's commitment to maintaining transparency while protecting market integrity.

The meeting schedule remains subject to potential changes due to exigencies that may arise from either the investor side or the company's requirements. Such flexibility is common in corporate investor interactions to accommodate unforeseen circumstances.

Company Background

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself in the alternative healthcare segment. The company's registered office is located in Zirakpur, Punjab, while its corporate office operates from New Delhi. The meeting details have also been made available on the company's official website at www.jeenasikho.com for broader stakeholder access.